IFNG and Alzheimer disease: Some recent studies demonstrate that treating animals with either CX3CL1 (fractalkine) or IFN-γ can affect microglia metabolic reprogramming, change their phenotype, and confer neuroprotection under ischemic and AD models, respectively [301,305], but this will require more research for translation to the clinic.